Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Dermatol Ther ; 33(6): e14499, 2020 11.
Artículo en Inglés | MEDLINE | ID: mdl-33141489

RESUMEN

INTRODUCTION: Conventional methods of basal cell carcinomas (BCC) treatment bring many severe side effects, especially, if they are repeated many times. The aim of this study is to present the clinical effectiveness of photodynamic method in the treatment and prevention of BCC relapses on the face and to propose a management algorithm. METHODS: In a patient with Gorlin-Goltz syndrome (NBCCS) lesions on the face were assessed clinically and with photodynamic diagnostics (PDD), initially and in follow-up every 3 months, for a total of 12 months. Detected BCCs were treated with photodynamic therapy three times every week. RESULTS: In whole follow-up period no clinical relapses were shown. However, in PDD after 6 month in one irradiated and in one initially clinically clear area red fluorescence indicating atypical foci was observed and irradiated additional one time. DISCUSSION: Photodynamic therapy is not limited by previous treatments, can be repeated without adverse events, heals multiple lesions at once and prevents new ones. Because BCC in NBCCS will occur constantly, the implementation of PDD to control the condition of the skin in long-term care should be obligatory. We indicate the validity of using the photodynamic diagnostic and therapy, as a medical procedures of choice.


Asunto(s)
Síndrome del Nevo Basocelular , Carcinoma Basocelular , Fotoquimioterapia , Neoplasias Cutáneas , Algoritmos , Síndrome del Nevo Basocelular/diagnóstico , Síndrome del Nevo Basocelular/tratamiento farmacológico , Carcinoma Basocelular/tratamiento farmacológico , Humanos , Recurrencia Local de Neoplasia/tratamiento farmacológico , Neoplasias Cutáneas/tratamiento farmacológico
2.
Acta Derm Venereol ; 98(7): 689-693, 2018 Jul 11.
Artículo en Inglés | MEDLINE | ID: mdl-29963684

RESUMEN

Actinic keratosis (AK) is the most common in situ cancerous skin lesion. Compared with other approved treatment modalities photodynamic therapy is preferred by patients due to faster recovery and improved cosmetic outcome. However, pain during irradiation is an important drawback. The aim of this study was to compare the effectiveness and tolerability of topical aminolaevulinic acid-photodynamic therapy in the treatment of AK on the head using red and green light. Complete remissions after 3 sessions of photodynamic therapy at 2-week intervals following 9 months of observation were 91.67% for red light and 86.67% for green light (difference not significant). The mean pain value was significantly greater in areas irradiated with red light compared with green light for all 3 sessions. This comparative study demonstrates that aminolaevulinic acid-photodynamic therapy with green light is of similar efficacy as that with red light in the treatment of middle/moderate AK, but causes less pain.


Asunto(s)
Ácido Aminolevulínico/administración & dosificación , Queratosis Actínica/tratamiento farmacológico , Fotoquimioterapia/métodos , Fármacos Fotosensibilizantes/administración & dosificación , Administración Cutánea , Anciano , Anciano de 80 o más Años , Ácido Aminolevulínico/efectos adversos , Femenino , Humanos , Queratosis Actínica/diagnóstico , Masculino , Persona de Mediana Edad , Dolor/etiología , Fotoquimioterapia/efectos adversos , Fármacos Fotosensibilizantes/efectos adversos , Polonia , Inducción de Remisión , Factores de Tiempo , Resultado del Tratamiento
4.
Med Sci Monit ; 18(2): PI5-9, 2012 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-22293891

RESUMEN

BACKGROUND: Common skin tumors like basal- and squamous-cell carcinoma present a serious problem in modern medicine. Exposure to ultraviolet solar radiation is the main cause of these lesions. Since application of Aldara and PDT separately is well documented, we decided to use both methods together. The aim of our study was to evaluate the effectiveness of local photodynamic therapy supplemented with topical application of Aldara in basal-cell carcinoma. MATERIAL/METHODS: Thirty-four patients ages 50 to 68 years were enrolled to the trial and underwent PDT treatment. Each case of BCC was histopathologically confirmed. Ten patients were subjected to local Levulan-PDT and placebo (Eucerin as vehicle cream), and 24 patients were subjected to Levulan-PDT and imiquimod. Photodynamic diagnosis (PDD) was used to detect and visualize suspicious foci (including cancer lesions). RESULTS: In the group of patients who were treated using Levulan-PDT and placebo, 6 patients (60%) were totally cured and 4 lesions (40%) significantly decreased in size. In the group of patients treated with Levulan-PDT and imiquimod, 18 lesions totally disappeared (75%), 6 lesions significantly diminished, and in 1 patient small foci of previously excised BCC developed again in scar tissue 10 month after the first control examination. CONCLUSIONS: Cure was achieved without any scarring and with very good cosmetic effects. Although this is the preliminary report, the presented modification of PDT seems to be reasonable and promising in treating basal-cell carcinoma.


Asunto(s)
Ácido Aminolevulínico/uso terapéutico , Carcinoma Basocelular/tratamiento farmacológico , Fotoquimioterapia , Fármacos Fotosensibilizantes/uso terapéutico , Neoplasias Cutáneas/tratamiento farmacológico , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia
5.
Cell Mol Biol Lett ; 15(4): 630-50, 2010 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-20865364

RESUMEN

Photodynamic therapy (PDT) is a well-known method for the treatment of malignant tumors, and its principles have been well established over the past 30 years. This therapy involves the application of a chemical called a photosensitizer and its subsequent excitation with light at the appropriate wavelength and energy. Topical photodynamic therapy with aminolevulinic acid (5-ALA) is an alternative therapy for many malignant processes, including nonmelanoma skin cancers such as basal-cell carcinoma (BCC). Our novel approach for this study was to use a liposomal formulation of 5-ALA and its methyl ester (commercially available as metvix) both in vitro and in vivo, and to check whether the liposome-entrapped precursors of photosensitizers can induce the expression of metalloproteinases (MMPs) in animal tumor cells and in other tissues from tumor-bearing rats and in selected cell lines in vitro. We also checked whether the application of tissue inhibitors of matrix metalloproteinases (TIMPs) has any effect on MMPs in the above-mentioned experimental models, and if they can cause complete inhibition of MMP expression. Immunohistochemical studies revealed that after the PDT, the intensity of expression of MMPs in healthy animals was very low and seen in single cells only. After the PDT in tumor-bearing rats, MMP-3 was expressed in the tumor cells with the highest intensity of staining in the tissues directly adjacent to the tumors, while MMP-2 and -9 were not found. In the control groups, there was no observed expression of MMPs. In vitro studies showed that MMP-3 was expressed in MCF-7 cells after PDT, but MMP-9 was not observed and MMP-2 was only seen in single cases. Our studies confirmed that the application of an MMP-3 inhibitor may block an induction of MMP-3 expression which had previously been initiated by PDT. The preliminary data obtained from cancer patients revealed that new precursors are effective in terms of PDT, and that using MMP inhibitors should be considered as a potential enhancing factor in clinical PDT.


Asunto(s)
Ácido Aminolevulínico/análogos & derivados , Línea Celular Tumoral/efectos de los fármacos , Liposomas , Metaloproteinasas de la Matriz/metabolismo , Fotoquimioterapia/métodos , Fármacos Fotosensibilizantes , Ácido Aminolevulínico/química , Ácido Aminolevulínico/farmacología , Ácido Aminolevulínico/uso terapéutico , Animales , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/enzimología , Neoplasias de la Mama/radioterapia , Supervivencia Celular/efectos de los fármacos , Femenino , Humanos , Isoenzimas/metabolismo , Liposomas/química , Liposomas/uso terapéutico , Fármacos Fotosensibilizantes/química , Fármacos Fotosensibilizantes/farmacología , Fármacos Fotosensibilizantes/uso terapéutico , Ratas , Ratas Wistar , Distribución Tisular
6.
J Biomed Biotechnol ; 2009: 919645, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-20069058

RESUMEN

Nuclear ubiquitous casein and cyclin-dependent kinases substrate (NUCKS) is 27 kDa chromosomal protein of unknown function. Its amino acid composition as well as structure of its DNA binding domain resembles that of high-mobility group A, HMGA proteins. HMGA proteins are associated with various malignancies. Since changes in expression of HMGA are considered as marker of tumor progression, it is possible that similar changes in expression of NUCKS could be useful tool in diagnosis and prognosis of breast cancer. For identification and analysis of NUCKS we used proteomic and histochemical methods. Analysis of patient-matched samples of normal and breast cancer by mass spectrometry revealed elevated levels of NUCKS in protein extracts from ductal breast cancers. We elicited specific antibodies against NUCKS and used them for immunohistochemistry in invasive ductal carcinoma of breast. We found high expression of NUCKS in 84.3% of cancer cells. We suggest that such overexpression of NUCKS can play significant role in breast cancer biology.


Asunto(s)
Neoplasias de la Mama/metabolismo , Carcinoma Ductal de Mama/metabolismo , Proteínas Nucleares/metabolismo , Fosfoproteínas/metabolismo , Proteómica , Anticuerpos Antineoplásicos/inmunología , Especificidad de Anticuerpos/inmunología , Neoplasias de la Mama/inmunología , Neoplasias de la Mama/patología , Carcinoma Ductal de Mama/inmunología , Carcinoma Ductal de Mama/patología , Femenino , Humanos , Inmunohistoquímica , Proteínas Nucleares/inmunología , Fosfoproteínas/inmunología
7.
J Environ Pathol Toxicol Oncol ; 25(1-2): 403-9, 2006.
Artículo en Inglés | MEDLINE | ID: mdl-16566731

RESUMEN

5-Aminolevulinic acid (5-ALA) is a well characterized precursor in the synthesis of various endogenous porphyrins used in photodynamic therapy (PDT). It is most often administered topically into a tumor which is then irradiated with visible light at established wavelength to sensitize porphyrins accumulated therein. Our main aim in the present study was to increase the penetration of 5-ALA through the altered skin by application of 3% azone (1-dodecyl-azepan-2-one) before the application of 20% 5-ALA in patients with plantar warts: mosaic warts (MW) and myrmecia (MY). We also used 20% 5-ALA only to treat warts in other patients. We compared the therapeutic and cosmetic effects of the two treatment modalities. The lesions treated with modification of 5-ALA-PDT by pretreatment with azone responded with better effectiveness. In 18 patients subjected to 5-ALA-PDT plus 3% azone, we observed 66.7% complete response of MW and 100% of MY following PDT repeated two or three times; whereas in other 18 patients treated with 5-ALA-PDT alone, we observed only 37.5% complete response of MW and 70% of MY. These results provide evidence that the pretreatment with azone should be considered as the step that enhances 5-ALA penetration in tissues and thus increases the effectiveness of applied PDT.


Asunto(s)
Azepinas/uso terapéutico , Fotoquimioterapia , Absorción Cutánea/efectos de los fármacos , Adolescente , Adulto , Ácido Aminolevulínico/uso terapéutico , Azepinas/administración & dosificación , Niño , Preescolar , Femenino , Humanos , Masculino , Fármacos Fotosensibilizantes/uso terapéutico , Verrugas
8.
Acta Dermatovenerol Croat ; 23(1): 52-8, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25969914

RESUMEN

Early diagnosis and therapy of precancerous lesions and malignant tumors belong to the most challenging tasks in modern medicine. Photodynamic diagnosis can help diagnose both precancerous lesions and early carcinoma. Actinic keratosis (AK) is the most common precancerous lesion of the skin. The available data show a high effectiveness of diclofenac in treating multifocal AK. We report a case of a 52-year-old woman who complained of multiple disseminated AK lesions predominantly on the lower limbs and trunk with a significant exacerbation within the last 6 months. Due to the spreading of disease and a high number of AK foci, as well as technical problems with visiting the hospital (PDT Laboratory), photodynamic therapy was not applied. The patient was treated for 2 months with a combination of local administration of 3% diclofenac and 0.1% tazaroten and 3% diclofenac only as a half side (left-right) comparison. The effects of therapy were later clinically evaluated and verified by means of photodynamic diagnosis (PDD) directly after therapy and at a follow-up examination 3 months later. The evaluation of treatment was blinded. Treatment with diclofenac only on the right side of the body resulted in clearing of 55% of all treated lesions, which increased to 60% three months after finishing therapy. On the left side of the body, where combined therapy (diclofenac 2 times daily on uneven dates and diclofenac once a day + tazaroten once a day on even dates) was used, 77.5% pathologic lesions disappeared, but this did not increase at follow up. The treatment of multifocal, disseminated AK is a difficult task and also burdensome for the patient due to side effects like scarring or burning and itching which occur during most therapies. Combined therapy with diclofenac and tazaroten supported by PDD may improve the effects of routine treatment of AK.


Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Fármacos Dermatológicos/uso terapéutico , Diclofenaco/uso terapéutico , Queratosis Actínica/tratamiento farmacológico , Ácidos Nicotínicos/uso terapéutico , Fotoquimioterapia , Quimioterapia Combinada , Femenino , Humanos , Persona de Mediana Edad , Resultado del Tratamiento
9.
J Exp Ther Oncol ; 4(2): 121-9, 2004 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-15503395

RESUMEN

5-aminolevulinic acid (5-ALA) is a precursor in synthesis of endogenous porphyrins used to sensitize tumor tissues in photodynamic therapy (PDT). It is administered topically into a tumor which after the certain time, required for porphyrins to accumulate, is irradiated with visible light from the proper source at established wavelength. Our main aim in the present study was to increase the penetration of 5-ALA through the skin and other tissues by addition of glycolic acid (GA) to 5-ALA on cell lines in vitro and on animals. We also applied 5-ALA ointment with glycolic acid to patients suffering from squamous cell carcinoma (SCC). In our study, we used 5-ALA, dimethyl sulfoxide (DMSO), ethylenediaminetetraacetic acid, disodium salt (EDTA) and GA together in one formulation (5-ALA-GA) on eucerin support. We compared both therapeutic and cosmetic effects in 5-ALA-GA-PDT and in control group of patients. Our results showed that modification of 5-ALA ointment by addition of 5% GA caused that the treated lesions responded with rapid regression. In 12 patients with single lesions of SCC type subjected to 5-ALA-GA-PDT, we observed 100% regression of tumors following single or repeated two-three times PDT. In vitro and in vivo in animals total porphyrin levels after addition of 5% GA increased significantly (P<0.01). These results provide evidence that addition of glycolic acid should be considered as the agent which enhances 5-ALA penetration in tissues and thus increases the effectiveness of photodynamic therapy.


Asunto(s)
Ácido Aminolevulínico/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Glicolatos/administración & dosificación , Neoplasias/tratamiento farmacológico , Fotoquimioterapia/métodos , Fármacos Fotosensibilizantes/administración & dosificación , Adenocarcinoma/tratamiento farmacológico , Administración Cutánea , Anciano , Animales , Carcinoma de Células Escamosas/tratamiento farmacológico , Línea Celular Tumoral , Neoplasias del Colon/tratamiento farmacológico , Dimetilsulfóxido/administración & dosificación , Ácido Edético/administración & dosificación , Femenino , Fibroblastos , Humanos , Masculino , Ratones , Ratones Endogámicos BALB C , Persona de Mediana Edad , Neoplasias Cutáneas/tratamiento farmacológico , Ensayos Antitumor por Modelo de Xenoinjerto
10.
Pol J Pathol ; 54(2): 117-21, 2003.
Artículo en Inglés | MEDLINE | ID: mdl-14575420

RESUMEN

In the present study we have checked whether photodynamic therapy (PDT) may influence concentration of basic Fibroblast Growth Factor (bFGF) in in vivo conditions. We have implanted malignant tumor, i.e. BFS1 fibrosarcoma into BALB/c mice and have them treated using well established photosensitizer, hematoporphyrin derivative and new compound, hydroxygallium (III) phthalocyanine tetrasulfonic acid tetrasodium salt, BON-6. The administration of those compounds was followed by light irradiation using a halogen lamp at proper wavelengths. Our results indicate that in vivo photodynamic therapy may cause a significant decrease in bFGF concentration and this phenomenon is accompanied by prolongation of survival of treated animals.


Asunto(s)
Factor 2 de Crecimiento de Fibroblastos/sangre , Fibrosarcoma/sangre , Fibrosarcoma/terapia , Fototerapia , Animales , Antineoplásicos/uso terapéutico , Trasplante de Células , Derivado de la Hematoporfirina/uso terapéutico , Ratones , Ratones Endogámicos BALB C , Compuestos Organometálicos/uso terapéutico , Fármacos Fotosensibilizantes/uso terapéutico
11.
Exp Ther Med ; 8(4): 1039-1046, 2014 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-25187794

RESUMEN

The aim of the present study was to investigate the immunohistochemical expression of nuclear ubiquitous casein and cyclin-dependent kinases substrate 1 (NUCKS1) in invasive breast carcinoma of no special type, in association with clinicopathological characteristics, including the tumor grade, frequency of lymph node involvement and distant metastasis. In addition, associations between NUCKS1 and other tumor subtype markers, including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), Ki-67 and cytokeratin 5/6 (CK 5/6), were investigated. NUCKS1 expression was shown to be associated with the formation of distant metastases and lymph node involvement. Furthermore, an association between the presence of NUCKS1 and histological grading was observed. The results confirmed that the expression of NUCKS1 in low grade invasive breast carcinoma of no special type was significantly less common compared with cases of high grade carcinoma. With regard to the additional tumor subtype markers, NUCKS1 expression was demonstrated to be significantly associated with Ki-67 and CK 5/6; however, no association was identified with ER, PR and HER2. Therefore, NUCKS1 may be a novel prognostic marker in the histopathological evaluation of invasive breast carcinoma of no special type.

12.
Photodiagnosis Photodyn Ther ; 10(4): 518-25, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-24284105

RESUMEN

BACKGROUND: Recent data indicates that nuclear ubiquitous casein and cyclin-dependent kinases substrate (NUCKS) may play role in tumor growth. In present study authors examined whether photodynamic therapy with 5-aminolevulinic acid (5-ALA) induces NUCKS expression in breast cancer cell line, MCF-7. METHODS: In the experiment concentration of 5-ALA was 6.5mM. Excitation wavelength was 630 ± 20 nm, total light dose of light 5 or 10 J/cm(2) and irradiance 60 mW/cm(2) was used. Cells were collected at established time points and Western blot and immunocytochemical studies were performed using antibody against NUCKS. RESULTS: Studies proved strong cytotoxic effects in cells following PDT with 6.5mM of precursor and 10 J/cm(2). Western blot analysis revealed the strongest expression of NUCKS at 7h after PDT. At next time points, 18 and 24h, expression of NUCKS decreased and became similar to that of control group. Further immunocytochemical studies showed very strong expression of NUCKS following PDT with 5-ALA and light irradiation of 5 J/cm(2). Early, at 0 h, that expression was predominantly seen in nuclei, while at 7h expression of NUCKS was observed in disseminated manner within entire cells in both nuclei and cytoplasm, with prevalence of cytoplasmic staining. CONCLUSIONS: Authors suggest that NUCKS is involved in cellular responses following PDT, and since parallel induction of NUCKS and proapoptotic marker Bax and inhibition of anti-apoptotic Bcl-2 was observed, this protein might also be involved in induction of apoptosis following PDT.


Asunto(s)
Ácido Aminolevulínico/uso terapéutico , Apoptosis/efectos de los fármacos , Apoptosis/efectos de la radiación , Biomarcadores de Tumor/metabolismo , Núcleo Celular/metabolismo , Proteínas Nucleares/metabolismo , Fosfoproteínas/metabolismo , Fotoquimioterapia/métodos , Núcleo Celular/efectos de los fármacos , Núcleo Celular/efectos de la radiación , Humanos , Células MCF-7 , Especificidad por Sustrato
13.
Comput Math Methods Med ; 2012: 793291, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22991578

RESUMEN

Fractal dimension analysis (FDA) is modern mathematical method widely used to describing of complex and chaotic shapes when classic methods fail. The main aim of this study was evaluating the influence of photodynamic therapy (PDT) with cystein proteases inhibitors (CPI) on the number and morphology of blood vessels inside tumor and on increase of effectiveness of combined therapy in contrast to PDT and CPI used separately. Animals were divided into four groups: control, treated using only PDT, treated using only CPI and treated using combined therapy, PDT and CPI. Results showed that time of animal survival and depth of necrosis inside tumor were significantly higher in CPI+PDT group in contrast to other groups. The higher value of fractal dimension (FD) was observed in control group, while the lowest value was found in the group which was treated by cystein protease inhibitors. The differences between FD were observed in CPI group and PDT+CPI group in comparison to control group. Our results revealed that fractal dimension analysis is a very useful tool in estimating differences between irregular shapes like blood vessels in PDT treated tumors. Thus, the implementation of FDA algorithms could be useful method in evaluating the efficacy of PDT.


Asunto(s)
Vasos Sanguíneos/patología , Inhibidores de Cisteína Proteinasa/farmacología , Fotoquimioterapia/métodos , Adenocarcinoma/patología , Algoritmos , Animales , Biología Computacional/métodos , Simulación por Computador , Femenino , Fractales , Neoplasias Mamarias Animales/patología , Modelos Teóricos , Necrosis , Trasplante de Neoplasias , Ratas , Ratas Wistar , Reproducibilidad de los Resultados , Programas Informáticos
15.
Med Sci Monit ; 9(4): BR110-4, 2003 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-12709661

RESUMEN

MATERIAL/METHODS: We implanted a malignant tumour, BFS1 fibrosarcoma, into BALB/c mice and then treated them using a new photosensitizer, hydroxygallium (III) phthalocyanine tetrasulfonic acid tetrasodium salt, BON-6. The administration of this compound was followed by light irradiation using a halogen lamp at 680 nm. VEGF concentrations were measured in sera from the mice and compared to the time of tumor growth. RESULTS: BON-6 was found to be effective in PDT. This feature was accompanied by low levels of VEGF after BON-6+PDT, and also prolongation of the time of survival of treated animals. The mice which received BON-6+PDT survived 83.8 days (SD 10.23). The mean survival time in control groups did not exceed 35 days. Additionally, measurement of tumor size showed total regression in single cases after BON-6+PDT. CONCLUSIONS: PDT, by decreasing VEGF serum levels, may influence the capability of tumor tissue to form new vessels.


Asunto(s)
Factores de Crecimiento Endotelial/sangre , Fibrosarcoma/tratamiento farmacológico , Péptidos y Proteínas de Señalización Intercelular/sangre , Linfocinas/sangre , Fotoquimioterapia , Animales , Fibrosarcoma/sangre , Ratones , Ratones Endogámicos BALB C , Neovascularización Patológica/tratamiento farmacológico , Neovascularización Patológica/metabolismo , Neovascularización Patológica/patología , Compuestos Organometálicos , Tasa de Supervivencia , Factores de Tiempo , Factor A de Crecimiento Endotelial Vascular , Factores de Crecimiento Endotelial Vascular
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA